JessicaE(Ravikoff)AllegrettiMD

Gastroenterology • Boston, MA

Associate Director, Crohn’s and Colitis Center

Join to view full profile

Dr. Allegretti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Allegretti's full profile

Already have an account?

Office
75 Francis St
# Brigham
Boston, MA 02115
Phone+1 617-732-6389

Summary

Dr. Jessica Allegretti is a gastroenterologist in Boston, MA and is affiliated with Brigham and Women's Hospital. She received her medical degree from University of Miami Leonard M. Miller School of Medicine and has been in practice 8 years. She is experienced in inflammatory bowel disease.

Education & Training

Brigham and Women's HospitalFellowship, Gastroenterology, 2012 - 2015
Massachusetts General HospitalResidency, Internal Medicine, 2009 - 2012
University of Miami Leonard M. Miller School of MedicineClass of 2009

Certifications & Licensure

MA State Medical License 2011 - 2026
NH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
CT State Medical License 2022 - 2024

Publications & Presentations

PubMed

Outcomes After Dose Intensification of Risankizumab for Crohn's Disease.
Rahul S Dalal, Heidy J Cabral, Alex Carlin, Matthew P Ilse, Jessica R Allegretti
Clinical Gastroenterology and Hepatology. 2024-12-09
International consensus statement on microbiome testing in clinical practice.
Serena Porcari, Benjamin H Mullish, Francesco Asnicar, Siew C Ng, Liping Zhao
The Lancet. Gastroenterology & Hepatology. 2024-12-05
Small-Molecule Neutrophil Modulator ADS051 Is Safe and Well-Tolerated in a Phase 1 Single Ascending Dose Study.
Adam S Cheifetz, Jessica R Allegretti, Megan Quintas, Bharat Dixit, Ronald Farquhar
The American Journal of Gastroenterology. 2024-11-26

Lectures

Clostridium difficile: Are We Making Progress?
AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/6/2018

Press Mentions

Four Analyses of Data for REBYOTA™ (Fecal Microbiota, Live – Jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile Infection, Presented at DDW 2023May 8th, 2023
FMT Tops Standard of Care for First or Second C. Diff InfectionsSeptember 29th, 2022
Opinion: Splashing Cold Water on Poop Transplants for Weight LossSeptember 1st, 2022
Join now to see all